Business
Jul 9, 2024, 9:01 PM
Jul 9, 2024, 10:38 AM
Daily Mail

MARKET REPORT: Indivior shares dive as it axes schizophrenia drug

Indivior specialty pharmaceuticals business
Daily Mail
/
Source
MARKET REPORT: Indivior shares dive as it axes schizophrenia drug

The London-listed pharma company will stop sales of its Perseris medicine because it said the monthly injection is 'no longer financially viable'.

Daily Mail
/
Source
Indivior cuts jobs and discontinues sales of schizophrenia medication

Indivior shares nosedived after the drugmaker slashed its profit guidance and revealed it would discontinue sales of a schizophrenia drug.

Opinions

You've reached the end